Literature DB >> 4017161

Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.

M Dufour, L C Panasci, J St Germain, L Boulet.   

Abstract

In human tumor cells freshly obtained from patients with breast cancer, ovarian cancer, or adenocarcinoma of unknown etiology and in normal human bone marrow cells, the cell-to-medium ratio (intracellular/extracellular concentration) in vitro of 5.42 microM melphalan rose rapidly to levels of 6-17 after 35 min at 37 degrees C in Dulbecco's phosphate-buffered saline containing bovine serum albumin and glucose. Only patient C (breast cancer) had received chemotherapy. In all cells studied, L amino acids (1 mM) such as leucine, glutamine, tyrosine, and methionine reduced the cell-to-medium ratio of melphalan at 3 and 35 min. There was a good correlation between the reduction of melphalan transport at 35 min in the heterogeneous nucleated bone marrow cell population by amino acids and their effect on melphalan cytotoxicity in the CFU-C system. Aminoisobutyric acid (A1B), a specific substrate of the A system of amino acid transport, at a concentration between 1 and 50 mM had no significant effect on melphalan uptake at 3 min in any of the human cells studied except those of patient C. At 35 min A1B (10 or 50 mM) significantly reduced the intracellular melphalan concentration in normal bone marrow cells and tumor cells from patients B and C. At 2 mM, 2-aminobicyclo-(2, 2,1)-heptane-2-carboxylic acid (BCH), a specific substrate of the L system of amino acid transport, reduced the cell-to-medium ratio to 70% of control at 3 and 35 min in human bone marrow cells. In tumor cells from patients A, B, D, and F, 2 mM BCH had no significant effect on melphalan uptake at 3 min; it slightly decreased uptake in tumor cells from patient C. At 35 min, 2 mM BCH significantly reduced melphalan transport in tumor cells from patients C and F only. The lack of a BCH-suppressible component to melphalan uptake into human tumor cells freshly obtained from previously untreated patients contrasts with the presence of this component in murine L1210 leukemia cells, murine P388 leukemia cells, and human tumor cell lines. This suggests that minor differences in melphalan transport may exist amongst species and also between human tumor cells which are freshly obtained and cell lines maintained in culture.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4017161     DOI: 10.1007/bf00257522

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

Review 1.  On the development of amino acid transport systems.

Authors:  H N Christensen
Journal:  Fed Proc       Date:  1973-01

2.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

3.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

4.  Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro.

Authors:  A Begleiter; H Y Lam; J Grover; E Froese; G J Goldenberg
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

5.  Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro.

Authors:  G J Goldenberg; M Lee; H Y Lam; A Begleiter
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

6.  Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content.

Authors:  K Suzukake; B P Vistica; D T Vistica
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

Review 7.  Amino acid transport in isolated rat hepatocytes.

Authors:  M S Kilberg
Journal:  J Membr Biol       Date:  1982       Impact factor: 1.843

8.  Evidence for two Na+-independent neutral amino acid transport systems in primary cultures of rat hepatocytes. Time-dependent changes in activity.

Authors:  L Weissbach; M E Handlogten; H N Christensen; M S Kilberg
Journal:  J Biol Chem       Date:  1982-10-25       Impact factor: 5.157

9.  Substrate specificity of a high-affinity, monovalent cation-dependent amino acid carrier.

Authors:  D T Vistica; B Schuette
Journal:  Biochem Biophys Res Commun       Date:  1979-09-12       Impact factor: 3.575

10.  Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells.

Authors:  D T Vistica
Journal:  Blood       Date:  1980-09       Impact factor: 22.113

View more
  5 in total

1.  Effect of L-leucine on oral melphalan kinetics in patients.

Authors:  P A Reece; B M Dale; R G Morris; D Kotasek; D Gee; S Rogerson; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues.

Authors:  J M Pankovich; K Jimbow
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

3.  Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.

Authors:  M A Alaoui-Jamali; L Panasci; G M Centurioni; R Schecter; S Lehnert; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.

Authors:  B C Millar; J A Maitland; J L Millar; J B Bell
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

5.  The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line.

Authors:  Y Kikuchi; I Iwano; M Miyauchi; T Kita; K Oomori; I Kizawa; M Sugita; Y Tenjin
Journal:  Jpn J Cancer Res       Date:  1988-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.